CanSino to begin phase 3 human trials for COVID-19 vaccine in Saudi Arabia

CanSino to begin phase 3 human trials for COVID-19 vaccine in Saudi Arabia

An adenoviral serotype 5 (Ad5) vectored COVID-19 vaccine candidate developed by the Chinese researchers is set to enter phase 3 clinical trial in Saudi Aradia, announced  CanSino Biologics.

The phase 2 trial results of the Ad5-nCOV vaccine candidate which was conducted in China had shown that the vaccine appeared to be safe and induced immune response, the results of which were published in the journal The Lancet.

The vaccine would be evaluated at the phase 3 trial which will involve 5,000 people, said a Saudi health ministry spokesperson to the media.

The vaccine is developed using a weakened human common cold virus (adenovirus) to deliver genetic material that codes for the SARS-CoV-2 spike protein to the cells. These cells then produce the spike protein and travel to the lymph nodes where the immune system creates antibodies that will recognize that spike protein and fight off the coronavirus.

The trial would test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam and Mecca, according to a Saudi news agency.